Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monovalent influenza modRNA vaccine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Monovalent influenza modRNA vaccine (mIRV) is an investigational vaccine candidate developed by Pfizer that utilizes nucleoside-modified messenger RNA (modRNA) technology. It is designed to encode the hemagglutinin protein of a single specific influenza strain, such as an Influenza A (H1N1 or H3N2) or Influenza B strain. By delivering the genetic instructions for the viral antigen, the vaccine prompts the host's cells to produce the protein, thereby eliciting a targeted immune response. This mRNA-based approach is intended to offer faster manufacturing timelines and potentially higher efficacy compared to traditional egg-based or cell-based influenza vaccines. mIRV has been evaluated in Phase 1/2 clinical trials both as a standalone monovalent agent and as a component of Pfizer's broader seasonal influenza vaccine program, which includes bivalent (bIRV) and quadrivalent (qIRV) formulations.
- Other names
- monovalent mRNA influenza vaccinemonovalent influenza mRNA vaccine
02
Targets
MHC II (Major histocompatibility complex class II receptor)Host sialic acid-containing glycoconjugate receptorBCR-H1 (B-cell receptor specific for influenza A H1 hemagglutinin)Innate immune RNA-sensing pattern-recognition receptorsHLA-B7Host cellular translation machinery
Beyond the preview
Go deeper on monovalent influenza modRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monovalent influenza modRNA vaccine.